AbbVie vs AXA: Founders, CEOs and History
AbbVie was founded in 2013 by Abbott Laboratories (spin-off origin) and is led by Robert A. Michael. AXA was founded in 1817 by Jacques-Théodore le Carpentier, Claude Bébéar and is led by Thomas Buberl.
Company facts
Founders
AbbVie
Abbott Laboratories (spin-off origin)
Abbott Laboratories was AbbVie's corporate predecessor. AbbVie's official launch materials describe the company as formed in 2013 following separation from Abbott. Richard A.
AXA
Jacques-Théodore le Carpentier
Little is recorded about le Carpentier beyond the founding act itself. In 1817 he and 17 other property owners in Rouen created the Compagnie d'Assurances Mutuelles contre l'Incendie for the departments of the Seine and the Eure, covering their own buildings a…
Claude Bébéar
Claude Bébéar built modern AXA. After joining in 1958 he spent 17 years inside the business, including 1964 to 1966 in Canada creating the life insurance arm of the group subsidiary Provinces Unies, before becoming chief executive in 1975 following Sahut d'Iza…
CEOs and their tenures
AbbVie
- Richard A. Gonzalez2013–2024
Founding Chairman and Chief Executive Officer
Served as AbbVie's chief executive officer from its formation in 2013 through June 2024 and as executive chairman through June 2025.
Source - Robert A. Michael2024–present
Chairman and Chief Executive Officer
Became chief executive officer on July 1, 2024 and chairman on July 1, 2025. He previously led finance, commercial operations, and corporate strategy roles at AbbVie.
Source
AXA
- Claude Bébéar1975–2000
Chairman and CEO
Bébéar turned a Normandy mutual into a global insurer between 1975 and 2000. He took control of the Drouot Group in 1982, bought Présence in 1986, merged with Compagnie du Midi in 1988, took control of The Equitable in the United States in 1991, National Mutua…
Source - Henri de Castries2000–2016
Chairman and CEO
De Castries ran AXA from May 2000 to September 2016, through the dot-com collapse, the 2008 financial crisis and the euro-area debt crisis, without state support.
Source - Thomas Buberl2016–present
Chief Executive Officer
Buberl became chief executive in September 2016 and refocused AXA on insurance underwriting.
Source
Timeline: AbbVie and AXA side by side
1817AXA
Founding of the Compagnie d'Assurances Mutuelles contre l'Incendie
Jacques-Théodore le Carpentier and 17 other property owners in Rouen set up a mutual fire insurance company, the earliest predecessor of AXA. It stayed a Normandy mutual, later called Ancienne Mutuelle, for more than a century.
1975AXA
Claude Bébéar becomes chief executive
Bébéar, recruited in 1958 by André Sahut d'Izarn, took over the Anciennes Mutuelles group in 1975 after Sahut d'Izarn's death and the settlement of a strike that had paralysed the company in April 1974.
1982AXA
Takeover of the Drouot Group
Bébéar took control of the Drouot Group, then the leading private French insurance group, and became its chairman alongside his role at Mutuelles Unies.
1985AXA
Creation of the AXA name
The group adopted the invented name AXA, short and pronounceable in any language, and Bébéar moved from running the insurance companies to chairing the group.
1986AXA
Acquisition of the Présence Group
AXA bought the Présence Group in April 1986, continuing the consolidation of French insurers.
1988AXA
Merger with Compagnie du Midi
The merger with Compagnie du Midi made AXA the second-largest French insurance group behind UAP and brought Equity and Law, then the sixth-largest life insurer in the United Kingdom. Bébéar was elected Manager of the Year the same year.
1991AXA
Control of The Equitable in the United States
After a failed attempt to buy Farmers, AXA agreed in July 1991 to demutualise and take control of The Equitable, then the fifth-largest life insurer in the United States, which also brought Alliance Capital Management.
1996AXA
Acquisition of UAP
AXA bought UAP, a French insurer twice its size, doubling its French business and reaching critical mass in the United Kingdom, Belgium and Germany. The merger took effect in 1997.
1999AXA
Guardian Royal Exchange and Nippon Dantai
Guardian Royal Exchange joined AXA in early 1999, adding scale in United Kingdom property, casualty and health insurance, and AXA took control of Nippon Dantai, then the thirteenth-largest life insurer in Japan.
2006AXA
Acquisition of Winterthur
AXA agreed to buy Winterthur from Credit Suisse for ~$14.8 billion (CHF 12.3 billion), about $8.93 billion (EUR 7.9 billion) in cash, strengthening its position in Switzerland, Germany and central and eastern Europe.
2011AXA
Sale of AXA Canada
AXA sold its Canadian operations to Intact Financial Corp. for ~$1.87 billion (C$2.6 billion) as part of a portfolio review.
2013AbbVie
AbbVie Launches as an Independent Company
AbbVie launched after Abbott Laboratories separated its research-based pharmaceutical business and began NYSE trading under ABBV.
2015AbbVie
Pharmacyclics Acquisition Completed
AbbVie completed its acquisition of Pharmacyclics, adding Imbruvica and expanding its hematologic oncology business.
2018AXA
Acquisition of XL Group
AXA bought XL Group for $15.3 billion in cash, shifting the group toward commercial property and casualty lines and creating the AXA XL platform.
2019AbbVie
Skyrizi Receives Initial U.S. Approval
The FDA approved Skyrizi for adults with moderate to severe plaque psoriasis in April 2019.
2019AbbVie
Rinvoq Receives Initial U.S. Approval
The FDA approved Rinvoq for adults with moderate to severe rheumatoid arthritis in August 2019.
2020AbbVie
Allergan Acquisition Completed
AbbVie completed the Allergan acquisition, adding neuroscience, eye care, and Allergan Aesthetics products including Botox and Juvederm.
2023AbbVie
U.S. Humira Biosimilar Competition Begins
Humira began facing U.S. biosimilar competition, and AbbVie reported a subsequent decline in Humira revenue.
2024AbbVie
ImmunoGen Acquisition Completed
AbbVie completed its acquisition of ImmunoGen, adding Elahere and antibody-drug conjugate programs.
2024AbbVie
Robert A. Michael Becomes CEO
Robert A. Michael succeeded Richard A. Gonzalez as chief executive officer effective July 1, 2024.
2024AbbVie
Cerevel Therapeutics Acquisition Completed
AbbVie completed its acquisition of Cerevel Therapeutics, adding clinical-stage neuroscience programs.
2024AXA
Launch of the Unlock the Future plan
With its 2023 results in February 2024 AXA presented a 2024 to 2026 plan targeting underlying earnings per share growth of 6% to 8% a year, an underlying return on equity of 14% to 16% and a new capital management policy.
2025AbbVie
Robert A. Michael Becomes Chairman
Robert A. Michael added the chairman role effective July 1, 2025, when Richard A. Gonzalez retired from the board.
2025AbbVie
FY2025 Revenue Reaches $61.160 Billion
AbbVie reported FY2025 net revenue of $61.160 billion and net income of $4.226 billion.
2025AXA
Sale of AXA Investment Managers to BNP Paribas
AXA completed the sale of AXA Investment Managers to BNP Paribas Cardif on July 1, 2025 for ~$5.76 billion (EUR 5.1 billion) in cash, a total transaction value of ~$6.1 billion (EUR 5.4 billion), and signed a long-term agreement for BNP Paribas to manage a lar…
2025AXA
Death of founder Claude Bébéar
AXA announced on November 4, 2025 that Claude Bébéar, its founder and Honorary Chairman, had died at the age of 90. He ran the group from 1975 to 2000 and created the AXA name in 1985.
2026AbbVie
Q1 2026 Revenue Reaches $15.002 Billion
AbbVie reported first-quarter 2026 net revenue of $15.002 billion, up 12.4 percent on a reported basis.
Acquisitions
AbbVie
- ImmunoGen, Inc.2024$10.1B
- Cerevel Therapeutics2024$8.7B
- Allergan plc2020$63B
- Pharmacyclics, Inc.2015$21B
AXA
- Prima Assicurazioni (51% stake)2025Undisclosed
- Laya Healthcare2023Undisclosed
- XL Group2018$15.3B
- Winterthur2006$10B
- UAP (Union des Assurances de Paris)1996$7.8B
- The Equitable (US)1991$1B
Questions about AbbVie vs AXA
Who is the CEO of AbbVie Inc. and AXA SA?
AbbVie Inc. is led by Robert A. Michael and AXA SA is led by Thomas Buberl. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was AbbVie Inc. founded vs AXA SA?
AXA SA was founded in 1817 — 196 years before AbbVie Inc., which was founded in 2013. AXA SA's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger AbbVie Inc..
How many employees does AbbVie Inc. have compared to AXA SA?
AbbVie Inc. employs approximately 57,000 people, while AXA SA employs approximately 156,000. AXA SA has the larger workforce at 156,000 employees, compared to AbbVie Inc.'s 57,000. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are AbbVie Inc. and AXA SA headquartered?
AbbVie Inc. is headquartered in United States and AXA SA is headquartered in France. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded AbbVie Inc. and AXA SA?
AbbVie Inc. was founded by Abbott Laboratories (spin-off origin). AXA SA was founded by Jacques-Théodore le Carpentier, Claude Bébéar.
Which company has a longer operating history — AbbVie Inc. or AXA SA?
AXA SA has been operating for approximately 209 years, making it the more established of the two companies. AbbVie Inc. has been in operation for around 13 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AbbVie vs AXA overview